Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-04-30

FDA Approved: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE — Supplemental Application (Jubilant Cadista Pharmaceuticals Inc.)

View source ↗

Summary

FDA approves a supplemental application for Jubilant Cadista's generic Losartan potassium and hydrochlorothiazide product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Losartan potassium and hydrochlorothiazide (losartan potassium and hydrochlorothiazide)

Snippet

SUPPL AP for LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE)